Synthetic cannabimimetics in Bulgaria 2010-2013

Drug and Alcohol Dependence

Volumn 157, Issue , 2015, Pages 200-204

  Andreeva Gateva, Pavlina A ^a,b   Nankova, Vasilka H ^a   Angelova, Violina T ^a   Gatev, Tzvetelin N ^c  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITY OF SOFIA   (Bulgaria)

^c Department of Forensic Medicine   (Bulgaria)

Author keywords

5F AkB 48; Forensic toxicology; JWH 018; MAM 2201; STS 135; UR 144

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; 5 F AKB 48; ILLICIT DRUG; MAM 2201; STS 135; SYNTHETIC CANNABIMIMETIC AGENT; UNCLASSIFIED DRUG; UR 144; (1-PENTYL-1H-INDOL-3-YL)(2,2,3,3-TETRAMETHYLCYCLOPROPYL)METHANONE; 1-(5-FLUOROPENTYL)-3-(4-METHYL-1-NAPHTHOYL)INDOLE; 1-PENTYL-3-(1-NAPHTHOYL)INDOLE; CANNABINOID; INDOLE DERIVATIVE; NAPHTHALENE DERIVATIVE; STREET DRUG;

ARTICLE; BULGARIA; HUMAN; INTOXICATION; LEGAL ASPECT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CHEMISTRY; FORENSIC TOXICOLOGY; STATISTICS AND NUMERICAL DATA;

BULGARIA; CANNABINOIDS; FORENSIC TOXICOLOGY; HUMANS; INDOLES; NAPHTHALENES; RETROSPECTIVE STUDIES; STREET DRUGS;

EID: 84951310194     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.10.019     Document Type: Article

References (36)

1. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 1993, 265:218-226.
2. Dresen S., Ferreiros N., Putz M., Westphal F., Zimmermann R., Auwarter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J. Mass Spectrom. 2010, 45:1186-1194. doi:10.1002/jms.1811.
3. EMCDDA, 2009. EMCDDA-Europol 2008 Annual Report on the implementation of Council Decision 2005/387/JHA 〈http://www.emcdda.europa.eu/html.cfm/index132901EN.html〉.
4. EMCDDA, 2013. 2013 National Report (2012 data) to the EMCDDA by the Reitox National Focl Point; Bulgaria; New Development, Trends and in-depth information on selected issues; Reitox 〈http://www.emcdda.europa.eu/html.cfm/index228349EN.html〉.
5. EMCDDA, 2014a. 2014 National Report (2013 data) to the EMCDDA by the Reitox National Focal Point; Bulgaria; New Development, Trends and in-depth information on selected issues; Reitox 〈http://www.emcdda.europa.eu/publications/national-reports/bulgaria-2014〉.
6. EMCDDA, 2014b. EMCDDA - Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA 〈http://www.emcdda.europa.eu/publications/implementation-reports/2013〉.
7. EMCDDA, 2015a. New psychoactive substances in Europe; An update from the EU Early Warning System (March 2015) 〈http://www.emcdda.europa.eu/publications/2015/new-psychoactive-substances〉.
8. EMCDDA, 2015b. New psychoactive substances in Europe; Innovative legal responses 〈http://www.emcdda.europa.eu/publications/2015/innovative-laws〉.
9. EMCDDA, 2015c. Perspectives on drugs; Synthetic cannabinoids in Europe 〈http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids〉.
10. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 2011, 117:15215-15217.
11. Gay, M., 2010. Synthetic marijuana spurs state bans. The New York Times, July 10 〈http://www.nytimes.com/2010/07/11/us/11k2.html?_r=0〉.
12. Gottardo R., Chiarini A., Dal Prà I., Seri C., Rimondo C., Serpelloni G., Armato U., Tagliaro F. Direct screening of herbal blends for new synthetic cannabinoids by MALDI-TOF MS. J. Mass Spectrom. 2012, 47:141-146.
13. Griffin G., Atkinson P.J., Showalter V.M., Martin B.R., Abood M.E. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J. Pharmacol. Exp. Ther. 1998, 285:553-560.
14. Grigoryev A., Kavanagh P., Melnik A., Savchuk S., Simonov A. Gas and liquid chromatography-mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J. Anal. Toxicol. 2013, 37:265-276.
15. Gurney S.M.R., Scott K.S., Kacinco S.I., Presley B.C., Logan B.K. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci. Rev. 2014, 26:53-78.
16. Hermanns-Clausen M., Kneisel S., Hutter M., Szabo B., Auwärter V. Acute intoxication by synthetic cannabinoids-four case reports. Drug Test Anal. 2013, 5:790-794.
17. Hermanns-Clausen M., Kneisel S., Szabo B., Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2012, 108:534-544.
18. Hu X., Primack B.A., Barnett T.E., Cook R.L. College students and use of K2: an emerging drug of abuse in young persons. Subst. Abuse Treat. Prev. Policy 2011, 6:16.
19. Hurst D., Loeffler G., McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am. J. Psychiatry 2011, 168:1119.
20. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., Beuerle T. Spice: a never ending story?. Forensic Sci. Int. 2009, 191:58-63.
21. Little P.J., Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 1988, 247:1046-1051.
22. Logan B.K., Reinhold L.E., Xu A., Diamond F.X. Identification of synthetic cannabinoids in herbal incense blends in the United States. J. Forensic Sci. 2012, 57:1168-1180.
23. McQuade D., Hudson S., Dargan P.I., Wood D.M. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur. J. Clin. Pharmacol. 2013, 69:373-376. (2).
24. Namera A., Kawamura M., Nakamoto A., Saito T., Nagao M. Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. Forensic Toxicol. 2015, 33:175-194.
25. NCSL, 2015. Synthetic drug threats 〈http://www.ncsl.org/research/civil-and-criminal-justice/synthetic-drug-threats.aspx〉.
26. Presley B.C., Jansen-Varnum S.A., Logan B.K. Analysis of synthetic cannabinoids in botanical material: a review of analytical methods and findings. Forensic Sci. Rev. 2013, 25:27-46.
27. Saito T., Namera A., Miura N., Ohta S., Miyazaki S., Osawa M., Inokuchi S. A fatal case of MAM-2201 poisoning. Forensic Toxicol. 2013, 31:333-337.
28. Stoykova S., Atanasov V., Kanev K. Analysis of synthetic cannabinoid JWH-018 in blood and urine by gas chromatography with mass spectrometry. MD-Medical Data 2015, 7:75-78. http://www.md-medicaldata.com/godina_2015_broj_1.html.
29. Tettey J., Crean C. New psychoactive substances: catalysing a shift in forensic science practice?. Philos. Trans. R. Soc. B 2015, 370:1674.
30. Thornton S.L., Wood C., Friesen M.W., Gerona R.R. Synthetic cannabinoid use associated with acute kidney injury. Clin. Toxicol. 2013, 51:189-190.
31. Uchiyama N., Kawamura M., Kikura-Hanajiri R., Goda Y. URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci. Int. 2013, 227:21-32.
32. UNODC, 2013a. The challenge of New Psychoactive Substances. Global SMART program 〈http://www.unodc.org/documents/scientific/NPS_2013_SMART.pdf〉.
33. UNODC, 2013b. Statistics 〈https://data.unodc.org/〉.
34. Van der Veer N., Friday J. Persistent psychosis following the use of Spice. Schizophr. Res. 2011, 130:285-286.
35. Winstock A.R., Barratt M.J. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013, 131:106-111.
36. Yeakel J.K., Logan B.K. Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J. Anal. Toxicol. 2013, 37:547-551.